secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001564590-21-055929
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS reports Q3 net loss $0.6M; BREXAFEMME net sales $0.5M in first partial quarter
--------------------------------------------------------------------------------

- BREXAFEMME net sales $0.5M in partial Q3; IQVIA 1,006 prescriptions in Q3, 1,100 in October.
- R&D expense $4.4M (-45% YoY); SG&A $15.4M (+341% YoY driven by commercial launch costs).
- Net loss $0.6M ($0.02 per basic share) vs net income $0.9M in Q3 2020.
- Cash $100.1M; runway projected into 2023.
- CFO Eric Francois resigning; Danforth Advisors providing interim CFO Lawrence Hoffman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000156459021055929/0001564590-21-055929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000156459021055929/scyx-8k_20211110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer